[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model

[Fam-] trastuzumab deruxtecan (DS-8201a) is a HER2 (ERBB2)-targeting antibody-drug conjugate, composed of a HER2-targeting antibody and a topoisomerase I inhibitor, exatecan derivative, that has antitumor effects in preclinical xenograft models and clinical trials. Recently, [fam-] trastuzumab derux...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Tomomi Nakayama, Sugihara, Kiyoshi, Wada, Teiji, Agatsuma, Toshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772042/
https://www.ncbi.nlm.nih.gov/pubmed/31574081
http://dx.doi.org/10.1371/journal.pone.0222280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772042/
https://www.ncbi.nlm.nih.gov/pubmed/31574081
http://dx.doi.org/10.1371/journal.pone.0222280

Ejemplares similares